TELES Informationstechnologien AG (TLIK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TELES Informationstechnologien AG (TLIK) has a cash flow conversion efficiency ratio of x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€12.77K ≈ $14.93K USD) by net assets (€0.00 ≈ $0.00 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TELES Informationstechnologien AG - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how TELES Informationstechnologien AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TELES Informationstechnologien AG (TLIK) total liabilities for a breakdown of total debt and financial obligations.
TELES Informationstechnologien AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TELES Informationstechnologien AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyanotech Corporation
NASDAQ:CYAN
|
-0.008x |
|
Rakovina Therapeutics Inc
V:RKV
|
-0.548x |
|
Winchester Energy Ltd
AU:WEL
|
-0.014x |
|
KEY Petroleum Ltd
AU:KEY
|
-0.230x |
|
Mantex AB
ST:MANTEX
|
0.076x |
|
Baronsmead Second Venture Trust Plc
LSE:BMD
|
-0.008x |
|
Bounty Oil & Gas NL
AU:BUY
|
-0.011x |
|
Uscom Ltd
AU:UCM
|
39.661x |
Annual Cash Flow Conversion Efficiency for TELES Informationstechnologien AG (2003–2024)
The table below shows the annual cash flow conversion efficiency of TELES Informationstechnologien AG from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see TLIK market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €0.00 ≈ $0.00 |
€-1.41 Million ≈ $-1.64 Million |
x | -- |
| 2023-12-31 | €-5.10 Million ≈ $-5.97 Million |
€193.00K ≈ $225.64K |
-0.038x | -59.33% |
| 2022-12-31 | €379.23K ≈ $443.36K |
€-9.00K ≈ $-10.52K |
-0.024x | +86.39% |
| 2021-12-31 | €1.61 Million ≈ $1.88 Million |
€-280.65K ≈ $-328.11K |
-0.174x | +99.76% |
| 2020-12-31 | €13.30K ≈ $15.55K |
€-986.42K ≈ $-1.15 Million |
-74.156x | -- |
| 2019-12-31 | €0.00 ≈ $0.00 |
€-660.30K ≈ $-771.96K |
x | -- |
| 2018-12-31 | €-9.46 Million ≈ $-11.06 Million |
€-1.04 Million ≈ $-1.22 Million |
0.110x | +15.21% |
| 2017-12-31 | €-9.62 Million ≈ $-11.25 Million |
€-920.00K ≈ $-1.08 Million |
0.096x | -22.97% |
| 2016-12-31 | €-10.15 Million ≈ $-11.86 Million |
€-1.26 Million ≈ $-1.47 Million |
0.124x | -7.88% |
| 2015-12-31 | €-13.19 Million ≈ $-15.42 Million |
€-1.78 Million ≈ $-2.08 Million |
0.135x | +859.46% |
| 2014-12-31 | €-11.75 Million ≈ $-13.73 Million |
€-165.00K ≈ $-192.90K |
0.014x | -91.34% |
| 2013-12-31 | €-10.33 Million ≈ $-12.07 Million |
€-1.68 Million ≈ $-1.96 Million |
0.162x | +187.11% |
| 2012-12-31 | €-10.65 Million ≈ $-12.45 Million |
€-602.00K ≈ $-703.80K |
0.057x | -89.49% |
| 2011-12-31 | €-7.73 Million ≈ $-9.03 Million |
€-4.15 Million ≈ $-4.86 Million |
0.538x | -1.95% |
| 2010-12-31 | €-7.21 Million ≈ $-8.43 Million |
€-3.95 Million ≈ $-4.62 Million |
0.548x | +146.47% |
| 2009-12-31 | €4.79 Million ≈ $5.59 Million |
€-5.65 Million ≈ $-6.60 Million |
-1.180x | -26.13% |
| 2008-12-31 | €12.02 Million ≈ $14.06 Million |
€-11.25 Million ≈ $-13.15 Million |
-0.935x | -644.25% |
| 2007-12-31 | €70.29 Million ≈ $82.17 Million |
€12.08 Million ≈ $14.12 Million |
0.172x | +319.22% |
| 2006-12-31 | €128.12 Million ≈ $149.78 Million |
€-10.04 Million ≈ $-11.74 Million |
-0.078x | +32.33% |
| 2005-12-31 | €133.96 Million ≈ $156.61 Million |
€-15.52 Million ≈ $-18.15 Million |
-0.116x | -122.40% |
| 2004-12-31 | €29.63 Million ≈ $34.64 Million |
€15.33 Million ≈ $17.92 Million |
0.517x | +15.67% |
| 2003-12-31 | €55.51 Million ≈ $64.89 Million |
€24.82 Million ≈ $29.02 Million |
0.447x | -- |
About TELES Informationstechnologien AG
Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.